MSA
5 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (NCT03829657) | Theravance Biopharma | 2019-02-22 |
| Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA (NCT03033680) | Brigham and Women's Hospital | 2017-03-24 |
| Mesenchymal Stem Cell Therapy in Multiple System Atrophy (NCT02315027) | Mayo Clinic | 2012-10-01 |
Track MSA automatically
Every clearance here is in the API, with alerts when new ones post.